Historically, especially within the first 20 years of p53 research, the connection of p53 with host immune response and regulation had been mostly limited to employing fragments of p53 protein as tumor-associated antigens (TAAs) for tumor vaccines [20,21,22] because many forms of p53 mutation stabilize the p53 protein, resulting in elevated p53 level in tumors [1,3,23,24]. Here, TP53 is linked to neoplasm.